TipRanks
Xvivo Perfusion AB (DE:3XV)
FRANKFURT:3XV

Xvivo Perfusion AB (3XV) Price & Analysis

0 Followers

3XV Stock Chart & Stats

€25.14
-€0.50(-2.30%)
At close: 4:00 PM EDT
€25.14
-€0.50(-2.30%)

Bulls Say, Bears Say

Bulls Say
Strong Organic GrowthThe broad-based growth indicates rising adoption of XVIVO’s transplantation technologies, especially in thoracic procedures. Strong sales expansion across the first nine months supports operating leverage, funds continued commercial investment, and strengthens the company’s position as transplant centers adopt advanced preservation workflows.
Regulatory And Product ExpansionHeart Assist Transport has achieved meaningful regulatory progress in Europe and the United States, expanding its addressable market beyond existing products. The broad EU indication and accepted U.S. application create a platform for future adoption, although commercialization remains dependent on approvals and reimbursement.
Financial FlexibilityVery low leverage gives XVIVO substantial financial flexibility to fund clinical trials, regulatory work, commercial expansion, and production capacity without relying heavily on debt. Recent positive cash generation further supports internal funding, even though the company’s longer-term cash-flow record has been uneven.
Bears Say
Component ConstraintsComponent shortages directly limit the company’s ability to convert customer demand into revenue, particularly in kidney products. Although management describes the issue as temporary, continued constraints over coming quarters could delay growth, weaken customer availability, and postpone the return to higher growth rates.
Margin And Services PressureWeak services revenue and negative services margin show that expansion of the surgical team and slower contract conversion are currently dilutive. Planned sales-force investment for future launches may create additional near-term margin pressure, making profitability less predictable while the growth infrastructure is built.
Customer Concentration RiskA major customer’s planned partial move to an internal EVLP platform could reduce thoracic revenue and utilization of XVIVO’s products. Management expects new-customer growth to offset the impact, but the transition creates execution risk because replacement volume must be developed before the customer loss is fully absorbed.

Xvivo Perfusion AB News

3XV FAQ

What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was €14.48 and its highest was €28.42 in the past 12 months.
    What is Xvivo Perfusion AB’s market cap?
    Xvivo Perfusion AB’s market cap is €586.45M.
      When is Xvivo Perfusion AB’s upcoming earnings report date?
      Xvivo Perfusion AB’s upcoming earnings report date is Jan 28, 2027 which is in 89 days.
        How were Xvivo Perfusion AB’s earnings last quarter?
        Xvivo Perfusion AB released its earnings results on Oct 22, 2026. The company reported €0.127 earnings per share for the quarter, beating the consensus estimate of €0.059 by €0.069.
          Is Xvivo Perfusion AB overvalued?
          According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Xvivo Perfusion AB pay dividends?
            Xvivo Perfusion AB does not currently pay dividends.
            What is Xvivo Perfusion AB’s EPS estimate?
            Xvivo Perfusion AB’s EPS estimate is 0.08.
              How many shares outstanding does Xvivo Perfusion AB have?
              Xvivo Perfusion AB has 31,499,470 shares outstanding.
                What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
                Xvivo Perfusion AB reported an EPS of €0.127 in its last earnings report, beating expectations of €0.059. Following the earnings report the stock price went up 1.175%.
                  Which hedge fund is a major shareholder of Xvivo Perfusion AB?
                  Currently, no hedge funds are holding shares in DE:3XV
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Xvivo Perfusion AB

                    Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.

                    Xvivo Perfusion AB (3XV) Earnings & Revenues

                    3XV Company Deck

                    3XV Earnings Call

                    Q3 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call was strongly positive overall, with 32% organic Q3 growth, improving EBITDA and cash flow, strong thoracic and heart momentum, major European and U.S. regulatory progress, and multiple expansion opportunities. The main challenges were temporary component and manufacturing-transfer constraints, weaker services revenue and margins, uncertainty around a major U.S. lung customer, reimbursement timing in Europe, competition in U.S. Liver, and planned near-term commercial investment that is expected to cause a slight margin dip.View all DE:3XV earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Getinge
                    ―
                    ―
                    Vitrolife AB
                    ―
                    ―
                    BICO Group AB Class B
                    ―
                    ―
                    SciBase Holding AB
                    ―
                    ―
                    Sedana Medical AB
                    ―
                    ―
                    Popular Stocks